Effects of topiramate on weight and metabolism in children with epilepsy.
OBJECTIVE
To explore the mechanism of topiramate-induced weight loss in epilepsy children by monitoring metabolism indices.


METHODS
Children with epilepsy were treated with topiramate at their first clinical visit. Metabolism indices including body mass index (BMI) and its SD scores, leptin, adiponectin, leptin/adiponectin (L/A), lipid profile-insulin and Homeostasis Model Assessments (HOMA) index were collected before and after treatment.


RESULTS
Topiramate treatment significantly reduced L/A (t = 2.156, p = 0.031), and markedly increased the serum level of adiponectin (t = 3.124, p = 0.002). Moreover, there were no relationships between the metabolism indices and dosages of topiramate (p > 0.05).


CONCLUSIONS
Our studies find that topiramate treatment in epilepsy children increases energy metabolism, resulting in weight loss. It has been demonstrated that adiponectin play a significant role in metabolic regulations.
Li
Hai-feng
HF
The Children's Hospital Zhejiang University School of Medicine, Hangzhou, China.
Zou
Yan
Y
Xia
Zhe-zhi
ZZ
Gao
Feng
F
Feng
Jian-hua
JH
Yang
Cui-wei
CW
D052242:Adiponectin / Q000097:blood; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D001786:Blood Glucose; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D016022:Case-Control Studies; D002648:Child; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D020738:Leptin / Q000097:blood; D008055:Lipids / Q000097:blood; D008297:Male; D008660:Metabolism / Q000187:drug effects; D018709:Statistics, Nonparametric; D000077236:Topiramate
D052242:Adiponectin; D019440:Anti-Obesity Agents; D001786:Blood Glucose; D007328:Insulin; D020738:Leptin; D008055:Lipids; D000077236:Topiramate; D005632:Fructose